Thus, small molecule inhibitors that only partially inhibit STAT1, such as of JAK1/JAK2 inhibitors, or indirectly inhibit STAT1 by targeting a subset of STAT1-dependent oncogenic signaling pathways, such as small molecule inhibitors of ARTD9 and DTX3L, might be the more suitable drugs for targeting the oncogenic functions of STAT1 in DLBCL. Here, DTX3L is linked to diffuse large B-cell lymphoma.